Tamsulosin Hydrochloride
Product Images NDC 53217-154

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Tamsulosin Hydrochloride (NDC 53217-154). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aidarex Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Tamsulosin HCl Usp 1)

FDA Label Image

Figure 1 Mean Plasma Tamsulosin Hydrochloride Concentrations Following Single-dose Administration Of Tamsulosin Hydrochloride Capsules 0.4 mg Under Fasted And Fed Conditions (n=8) (Tamsulosin HCl Usp 2)

Figure 1 Mean Plasma Tamsulosin Hydrochloride Concentrations Following Single-dose Administration Of Tamsulosin Hydrochloride Capsules 0.4 mg Under Fasted And Fed Conditions (n=8) (Tamsulosin HCl Usp 2)
This appears to be a figure showing the mean plasma tamsulosin hydrochloride concentrations following single-dose administration of 0.4 mg tamsulosin hydrochloride capsules. The figure shows the concentrations under both fasted and fed conditions over a period of time in hours. Without additional information or context, it's unclear what the specific purpose or findings of this figure are.*
FDA Label Image

Figure 2a Mean Change From Baseline In Total Aua Symptom Score (0 To 35) Study 1 (Tamsulosin HCl Usp 3)

Figure 2a Mean Change From Baseline In Total Aua Symptom Score (0 To 35) Study 1 (Tamsulosin HCl Usp 3)
This is a graph showing the mean change from the baseline in the total AUA Symptom Score. The study had two groups, one taking treatment and another taking the placebo. The duration of treatment lasted for several weeks. No other information is available.*
FDA Label Image

Figure 2b Mean Change From Baseline In Total Aua Symptom Score (0 To 35) Study 2 (Tamsulosin HCl Usp 4)

Figure 2b Mean Change From Baseline In Total Aua Symptom Score (0 To 35) Study 2 (Tamsulosin HCl Usp 4)
The figure shows the mean change from the baseline in the total AUA symptom score achieved in Study 2. Treatment groups include O.4mg LNt, O.O8mg LNt, and placebo. The duration of treatment is measured in weeks. No additional information is available.*
FDA Label Image

Figure 3a Mean Increase In Peak Urine Flow Rate (ml/sec) Study 1 (Tamsulosin HCl Usp 5)

Figure 3a Mean Increase In Peak Urine Flow Rate (ml/sec) Study 1 (Tamsulosin HCl Usp 5)
This is a graph (Figure 3A) that shows the mean increase in peak urine flow rate (in L/sec) in Study 1. It compares three different treatments: 0.08 mg, 2x 0.4 mg, and placebo. The mean change in mL/sec is plotted on the y-axis, and the duration of treatment (in weeks) is plotted on the x-axis. The study included a total of 3,380 participants across all treatments.*
FDA Label Image

Figure 3b Mean Increase In Peak Urine Flow Rate (ml/sec) Study 2 (Tamsulosin HCl Usp 6)

Figure 3b Mean Increase In Peak Urine Flow Rate (ml/sec) Study 2 (Tamsulosin HCl Usp 6)
The text appears to show a figure titled "Figure 3B" with the label "Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 2". It includes a chart with a horizontal axis labeled "Duration of Treatment (weeks)" and a vertical axis labeled in "mL/Sec". There is also a legend indicating a treatment group, but the specific details of the values or outcomes are not clear due to the quality.*
FDA Label Image

Image Description (Tamsulosin HCl Usp 7)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.